A Systematic Review of Esophageal MicroRNA Markers for Diagnosis and Monitoring of Barrett’s Esophagus

Digestive Diseases and Sciences

Volumn 61, Issue 4, 2016, Pages 1039-1050

  Mallick, Reema ^a   Patnaik, Santosh K ^b   Wani, Sachin ^c   Bansal, Ajay ^d,e  

^a UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

^b ROSWELL PARK CANCER INSTITUTE   (United States)

^c UNIVERSITY OF COLORADO   (United States)

^d VETERANS AFFAIRS MEDICAL CENTER   (United States)

^e UNIVERSITY OF KANSAS SCHOOL OF MEDICINE   (United States)

Author keywords

Barrett s esophagus; Esophageal adenocarcinoma; Gastroesophageal reflux disease; MicroRNA

Indexed keywords

BIOLOGICAL MARKER; MICRORNA; MICRORNA 192; MICRORNA 194; MICRORNA 203; MICRORNA 205; MICRORNA 215; UNCLASSIFIED DRUG;

ARTICLE; BARRETT ESOPHAGUS; CANCER TISSUE; DEMOGRAPHY; ESOPHAGEAL ADENOCARCINOMA; ESOPHAGUS DYSPLASIA; ESOPHAGUS MUCOSA; GENE EXPRESSION; HUMAN; PRIORITY JOURNAL; SCREENING; SYSTEMATIC REVIEW; ADENOCARCINOMA; COMPLICATION; ESOPHAGEAL NEOPLASMS; METABOLISM;

ADENOCARCINOMA; BARRETT ESOPHAGUS; BIOMARKERS; ESOPHAGEAL NEOPLASMS; HUMANS; MICRORNAS;

EID: 84961166975     PISSN: 01632116     EISSN: 15732568     Source Type: Journal    
DOI: 10.1007/s10620-015-3959-3     Document Type: Article

References (52)

1. Hur C, Miller M, Kong CY, et al. Trends in esophageal adenocarcinoma incidence and mortality. Cancer. 2013;119:1149–1158.
2. Prasad GA, Wu TT, Wigle DA, et al. Endoscopic and surgical treatment of mucosal (T1a) esophageal adenocarcinoma in Barrett’s esophagus. Gastroenterology. 2009;137:815–823.
3. Shaheen NJ, Sharma P, Overholt BF, et al. Radiofrequency ablation in Barrett’s esophagus with dysplasia. N Engl J Med. 2009;360:2277–2288.
4. Shaheen NJ, Hur C. Garlic, silver bullets, and surveillance upper endoscopy for Barrett’s esophagus. Gastroenterology. 2013;145:273–276.
5. Spechler SJ, Souza RF. Barrett’s esophagus. N Engl J Med. 2014;371:836–845.
6. Sharma P. Clinical practice. Barrett’s esophagus. N Engl J Med. 2009;361:2548–2556.
7. Reid BJ. Early events during neoplastic progression in Barrett’s esophagus. Cancer Biomark. 2010;9:307–324.
8. Prasad GA, Bansal A, Sharma P, Wang KK. Predictors of progression in Barrett’s esophagus: current knowledge and future directions. Am J Gastroenterol. 2010;105:1490–1502.
9. Theisen J, Stein HJ, Dittler HJ, et al. Preoperative chemotherapy unmasks underlying Barrett’s mucosa in patients with adenocarcinoma of the distal esophagus. Surg Endosc. 2002;16:671–673.
10. Ross-Innes CS, Debiram-Beecham I, O’Donovan M, et al. Evaluation of a minimally invasive cell sampling device coupled with assessment of trefoil factor 3 expression for diagnosing Barrett’s esophagus: a multi-center case–control study. PLoS Med. 2015;12:e1001780.
11. Kastelein F, Biermann K, Steyerberg EW, et al. Aberrant p53 protein expression is associated with an increased risk of neoplastic progression in patients with Barrett’s oesophagus. Gut. 2013;62:1676–1683.
12. Lujambio A, Lowe SW. The microcosmos of cancer. Nature. 2012;482:347–355.
13. Lu J, Getz G, Miska EA, et al. MicroRNA expression profiles classify human cancers. Nature. 2005;435:834–838.
14. Saito M, Shiraishi K, Matsumoto K, et al. A three-microRNA signature predicts responses to platinum-based doublet chemotherapy in patients with lung adenocarcinoma. Clin Cancer Res. 2014;20:4784–4793.
15. Bansal A, Lee IH, Hong X, et al. Feasibility of microRNAs as biomarkers for Barrett’s esophagus progression: a pilot cross-sectional, phase 2 biomarker study. Am J Gastroenterol. 2011;106:1055–1063.
16. Smith CM, Michael MZ, Watson DI, et al. Impact of gastro-oesophageal reflux on microRNA expression, location and function. BMC Gastroenterol. 2013;13:4.
17. Bansal A, Lee IH, Hong X, et al. Discovery and validation of Barrett’s esophagus microRNA transcriptome by next generation sequencing. PLoS ONE. 2013;8:e54240.
18. Fassan M, Volinia S, Palatini J, et al. MicroRNA expression profiling in human Barrett’s carcinogenesis. Int J Cancer. 2011;129:1661–1670.
19. Fassan M, Volinia S, Palatini J, et al. MicroRNA expression profiling in the histological subtypes of Barrett’s metaplasia. Clin Transl Gastroenterol. 2013;4:e34.
20. Feber A, Xi L, Luketich JD, et al. MicroRNA expression profiles of esophageal cancer. J Thorac Cardiovasc Surg. 2008;135:255–260. (discussion 260).
21. Wu X, Ajani JA, Gu J, et al. MicroRNA expression signatures during malignant progression from Barrett’s esophagus to esophageal adenocarcinoma. Cancer Prev Res (Phila). 2013;6:196–205.
22. Garman KS, Owzar K, Hauser ER, et al. MicroRNA expression differentiates squamous epithelium from Barrett’s esophagus and esophageal cancer. Dig Dis Sci. 2013;58:3178–3188.
23. Kan T, Meltzer SJ. MicroRNAs in Barrett’s esophagus and esophageal adenocarcinoma. Curr Opin Pharmacol. 2009;9:727–732.
24. Kan T, Sato F, Ito T, et al. The miR-106b-25 polycistron, activated by genomic amplification, functions as an oncogene by suppressing p21 and Bim. Gastroenterology. 2009;136:1689–1700.
25. Leidner RS, Ravi L, Leahy P, et al. The microRNAs, MiR-31 and MiR-375, as candidate markers in Barrett’s esophageal carcinogenesis. Genes Chromosomes Cancer. 2012;51:473–479.
26. Luzna P, Gregar J, Uberall I, Radova L, Prochazka V, Ehrmann J Jr. Changes of microRNAs-192, 196a and 203 correlate with Barrett’s esophagus diagnosis and its progression compared to normal healthy individuals. Diagn Pathol. 2011;6:114.
27. Maru DM, Singh RR, Hannah C, et al. MicroRNA-196a is a potential marker of progression during Barrett’s metaplasia–dysplasia–invasive adenocarcinoma sequence in esophagus. Am J Pathol. 2009;174:1940–1948.
28. Mathe EA, Nguyen GH, Bowman ED, et al. MicroRNA expression in squamous cell carcinoma and adenocarcinoma of the esophagus: associations with survival. Clin Cancer Res. 2009;15:6192–6200.
29. Matsuzaki J, Suzuki H, Tsugawa H, et al. Bile acids increase levels of microRNAs 221 and 222, leading to degradation of CDX2 during esophageal carcinogenesis. Gastroenterology. 2013;145:1300–1311.
30. Revilla-Nuin B, Parrilla P, Lozano JJ, et al. Predictive value of microRNAs in the progression of Barrett esophagus to adenocarcinoma in a long-term follow-up study. Ann Surg. 2013;257:886–893.
31. van Baal JW, Verbeek RE, Bus P, et al. MicroRNA-145 in Barrett’s oesophagus: regulating BMP4 signalling via GATA6. Gut. 2012;62:664–675.
32. Wijnhoven BP, Hussey DJ, Watson DI, Tsykin A, Smith CM, Michael MZ. MicroRNA profiling of Barrett’s oesophagus and oesophageal adenocarcinoma. Br J Surg. 2010;97:853–861.
33. Yang H, Gu J, Wang KK, et al. MicroRNA expression signatures in Barrett’s esophagus and esophageal adenocarcinoma. Clin Cancer Res. 2009;15:5744–5752.
34. Saad R, Chen Z, Zhu S, et al. Deciphering the unique microRNA signature in human esophageal adenocarcinoma. PLoS ONE. 2013;8:e64463.
35. McShane LM, Altman DG, Sauerbrei W, Taube SE, Gion M, Clark GM. Reporting recommendations for tumor marker prognostic studies (REMARK). J Natl Cancer Inst. 2005;97:1180–1184.
36. Altman DG, Bland JM. How to obtain the confidence interval from a P value. BMJ. 2011;343:d2090.
37. Streppel MM, Pai S, Campbell NR, et al. MicroRNA 223 is upregulated in the multistep progression of Barrett’s esophagus and modulates sensitivity to chemotherapy by targeting PARP1. Clin Cancer Res. 2013;19:4067–4078.
38. Chen Z, Saad R, Jia P, et al. Gastric adenocarcinoma has a unique microRNA signature not present in esophageal adenocarcinoma. Cancer. 2013;119:1985–1993.
39. Altman DG, McShane LM, Sauerbrei W, Taube SE. Reporting Recommendations for Tumor Marker Prognostic Studies (REMARK): explanation and elaboration. PLoS Med. 2012;9:e1001216.
40. Pepe MS, Etzioni R, Feng Z, et al. Phases of biomarker development for early detection of cancer. J Natl Cancer Inst. 2001;93:1054–1061.
41. Smith E, De Young NJ, Pavey SJ, et al. Similarity of aberrant DNA methylation in Barrett’s esophagus and esophageal adenocarcinoma. Mol Cancer. 2008;7:75.
42. Meyer SU, Pfaffl MW, Ulbrich SE. Normalization strategies for microRNA profiling experiments: a ‘normal’ way to a hidden layer of complexity? Biotechnol Lett. 2010;32:1777–1788.
43. Slaby O, Srovnal J, Radova L, et al. Dynamic changes in microRNA expression profiles reflect progression of Barrett’s esophagus to esophageal adenocarcinoma. Carcinogenesis. 2015;36:521–527.
44. Lee IH, Hong X, Mathur SC, et al. A detailed analysis of next generation sequencing reads of microRNA expression in Barrett’s esophagus: absolute versus relative quantification. BMC Res Notes. 2014;7:212.
45. Ozsolak F, Milos PM. RNA sequencing: advances, challenges and opportunities. Nat Rev Genet. 2011;12:87–98.
46. Nones K, Waddell N, Wayte N, et al. Genomic catastrophes frequently arise in esophageal adenocarcinoma and drive tumorigenesis. Nat Commun. 2014;5:5224.
47. Rugge M, Zaninotto G, Parente P, et al. Barrett’s esophagus and adenocarcinoma risk: the experience of the North-Eastern Italian Registry (EBRA). Ann Surg. 2012;256:788–794. (discussion 794-785).
48. Sharma P, Falk GW, Weston AP, Reker D, Johnston M, Sampliner RE. Dysplasia and cancer in a large multicenter cohort of patients with Barrett’s esophagus. Clin Gastroenterol Hepatol. 2006;4:566–572.
49. Reid BJ, Sanchez CA, Blount PL, Levine DS. Barrett’s esophagus: cell cycle abnormalities in advancing stages of neoplastic progression. Gastroenterology. 1993;105:119–129.
50. Kadri SR, Lao-Sirieix P, O’Donovan M, et al. Acceptability and accuracy of a non-endoscopic screening test for Barrett’s oesophagus in primary care: cohort study. BMJ. 2010;341:c4372.
51. Abrams JA, Appelman HD, Beer DG, et al. Barrett’s Esophagus Translational Research Network (BETRNet): the pivotal role of multi-institutional collaboration in esophageal adenocarcinoma research. Gastroenterology. 2014;146:1586–1590.
52. Chiam K, Wang T, Watson DI, et al. Circulating serum exosomal miRNAs as potential biomarkers for esophageal adenocarcinoma. J Gastrointest Surg. 2015;19:1208–1215.